Mark Henkemeyer Selected Research

EphB1 Receptor

1/2021	Identification of tetracycline combinations as EphB1 tyrosine kinase inhibitors for treatment of neuropathic pain.
4/2015	Knockdown of EphB1 receptor decreases medulloblastoma cell growth and migration and increases cellular radiosensitization.
7/2011	Blocking EphB1 receptor forward signaling in spinal cord relieves bone cancer pain and rescues analgesic effect of morphine treatment in rodents.
11/2008	Targeted mutation of EphB1 receptor prevents development of neuropathic hyperalgesia and physical dependence on morphine in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark Henkemeyer Research Topics

Disease

3	Neuralgia (Stump Neuralgia) 01/2021 - 11/2008
3	Pain (Aches) 01/2013 - 11/2008
2	Inflammation (Inflammations) 01/2021 - 01/2018
2	Neoplasms (Cancer) 12/2016 - 11/2009
2	Cleft Palate (Palate, Cleft) 02/2011 - 03/2009
1	Chronic Renal Insufficiency 01/2021
1	Neurodevelopmental Disorders 01/2021
1	Ischemia 01/2021
1	Fibrosis (Cirrhosis) 01/2021
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2018
1	Melanoma (Melanoma, Malignant) 12/2016
1	Breast Neoplasms (Breast Cancer) 12/2016
1	Medulloblastoma 04/2015
1	Lung Diseases (Lung Disease) 10/2013
1	Chronic Pain 01/2013
1	Laryngeal cleft 10/2012
1	Ganglion Cysts (Ganglion) 03/2012
1	Herpes Zoster 10/2011
1	Bone Neoplasms (Bone Cancer) 07/2011
1	Congenital Abnormalities (Deformity) 07/2011
1	Carcinoma (Carcinomatosis) 11/2009
1	Adenoma (Adenomas) 11/2009
1	Opioid-Related Disorders (Opiate Addiction) 11/2008
1	Hyperalgesia 11/2008
1	Peripheral Nerve Injuries 11/2008
1	Morphine Dependence 11/2008
1	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2007
1	Brain Injuries (Brain Injury) 12/2007
1	Hypospadias 10/2007
1	Anorectal Malformations 10/2007
1	Polyps 09/2002
1	Peutz-Jeghers Syndrome (Polyposis, Hamartomatous Intestinal) 09/2002
1	Tetanus 06/2002

Drug/Important Bio-Agent (IBA)

5	EphrinsIBA 01/2021 - 06/2002
4	LigandsIBA 01/2021 - 06/2002
4	EphB1 ReceptorIBA 01/2021 - 11/2008
3	Phosphotransferases (Kinase)IBA 01/2021 - 11/2008
3	Ephrin-B2 (Ephrin B2)IBA 12/2016 - 10/2007
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2021 - 01/2021
2	EphB2 ReceptorIBA 01/2021 - 03/2009
2	CytokinesIBA 01/2021 - 01/2018
2	Proteins (Proteins, Gene)FDA Link 04/2015 - 03/2009
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2013 - 07/2011
2	Tyrosine (L-Tyrosine)FDA Link 10/2011 - 11/2008
2	Indicators and Reagents (Reagents)IBA 07/2011 - 11/2008
2	Morphine (MS Contin)FDA LinkGeneric 07/2011 - 11/2008
2	Eph Family Receptors (Eph Receptors)IBA 11/2009 - 11/2008
1	Carrier Proteins (Binding Protein)IBA 01/2021
1	EphA1 Receptor (Eph Receptor)IBA 01/2021
1	Minocycline (Cyclops)FDA LinkGeneric 01/2021
1	Tetracycline (Achromycin)FDA LinkGeneric 01/2021
1	Chlortetracycline (Aureomycin)FDA Link 01/2021
1	Demeclocycline (Declomycin)FDA LinkGeneric 01/2021
1	Erythropoietin FDA Link 01/2021
1	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2021
1	Glutamate Receptors (Glutamate Receptor)IBA 01/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	ChemokinesIBA 01/2018
1	Messenger RNA (mRNA)IBA 04/2015
1	tyrosine receptor (receptor, tyrosine)IBA 04/2015
1	N-Methylaspartate (NMDA)IBA 01/2013
1	GalactosidasesIBA 10/2012
1	Retinaldehyde (Retinal)IBA 03/2012
1	Analgesics (Analgesic Drugs)IBA 07/2011
1	Transforming Growth Factors (Transforming Growth Factor)IBA 02/2011
1	Cyclin D1IBA 11/2009
1	Ephrin-B3 (Ephrin B3)IBA 12/2007
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 09/2002
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 09/2002
1	ColforsinIBA 06/2002

Therapy/Procedure

1	Therapeutics 10/2013